Bellevue Group AG Acquires 2,250 Shares of Quest Diagnostics Incorporated (NYSE:DGX)

Bellevue Group AG boosted its holdings in Quest Diagnostics Incorporated (NYSE:DGXGet Rating) by 17.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,250 shares of the medical research company’s stock after acquiring an additional 2,250 shares during the period. Bellevue Group AG’s holdings in Quest Diagnostics were worth $2,638,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Anfield Capital Management LLC lifted its position in Quest Diagnostics by 1,077.8% during the fourth quarter. Anfield Capital Management LLC now owns 212 shares of the medical research company’s stock worth $37,000 after acquiring an additional 194 shares during the last quarter. Lindbrook Capital LLC increased its stake in shares of Quest Diagnostics by 62.3% during the fourth quarter. Lindbrook Capital LLC now owns 245 shares of the medical research company’s stock worth $42,000 after purchasing an additional 94 shares during the period. Glassman Wealth Services lifted its holdings in Quest Diagnostics by 57.1% during the 3rd quarter. Glassman Wealth Services now owns 297 shares of the medical research company’s stock worth $43,000 after purchasing an additional 108 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in Quest Diagnostics by 762.9% in the 3rd quarter. Jones Financial Companies Lllp now owns 302 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 267 shares during the period. Finally, Cordasco Financial Network acquired a new position in Quest Diagnostics in the 3rd quarter valued at $48,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Shares of DGX traded down $2.14 during midday trading on Tuesday, hitting $134.07. The company’s stock had a trading volume of 22,457 shares, compared to its average volume of 1,248,244. The company has a quick ratio of 1.34, a current ratio of 1.46 and a debt-to-equity ratio of 0.62. Quest Diagnostics Incorporated has a one year low of $125.77 and a one year high of $174.16. The stock has a market capitalization of $15.74 billion, a price-to-earnings ratio of 8.90 and a beta of 1.05. The company’s fifty day simple moving average is $138.05 and its two-hundred day simple moving average is $144.41.

Quest Diagnostics (NYSE:DGXGet Rating) last issued its earnings results on Thursday, April 21st. The medical research company reported $3.22 EPS for the quarter, topping the consensus estimate of $2.92 by $0.30. The firm had revenue of $2.61 billion during the quarter, compared to the consensus estimate of $2.64 billion. Quest Diagnostics had a return on equity of 27.08% and a net margin of 17.61%. The business’s quarterly revenue was down 4.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.76 earnings per share. On average, research analysts predict that Quest Diagnostics Incorporated will post 9.31 earnings per share for the current year.

In other news, SVP Catherine T. Doherty sold 2,750 shares of Quest Diagnostics stock in a transaction dated Thursday, February 24th. The stock was sold at an average price of $126.26, for a total transaction of $347,215.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Michael E. Prevoznik sold 6,228 shares of the company’s stock in a transaction that occurred on Tuesday, March 8th. The shares were sold at an average price of $135.21, for a total value of $842,087.88. The disclosure for this sale can be found here. 1.45% of the stock is owned by corporate insiders.

A number of equities research analysts have recently issued reports on the stock. Citigroup cut shares of Quest Diagnostics from a “buy” rating to a “neutral” rating and reduced their target price for the company from $175.00 to $140.00 in a research report on Monday, April 4th. Robert W. Baird cut their price objective on shares of Quest Diagnostics from $162.00 to $146.00 in a report on Friday, February 4th. Morgan Stanley lowered their target price on shares of Quest Diagnostics from $159.00 to $145.00 and set an “equal weight” rating on the stock in a report on Monday, February 14th. Deutsche Bank Aktiengesellschaft cut Quest Diagnostics from a “buy” rating to a “hold” rating and cut their price target for the company from $190.00 to $129.00 in a research note on Friday, January 28th. Finally, Wells Fargo & Company raised their price objective on Quest Diagnostics from $145.00 to $150.00 and gave the stock an “equal weight” rating in a research note on Monday, April 25th. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Quest Diagnostics has a consensus rating of “Hold” and an average price target of $150.92.

Quest Diagnostics Company Profile (Get Rating)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

See Also

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGXGet Rating).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.